Cytocom, Inc. is a clinical-stage biopharmaceutical company developing novel second-generation immune therapies to deliver immune homeostasis based on proprietary platforms. The company has four phases 3 ready programs in Crohn’s Disease, Fibromyalgia, MS, and Pancreatic Cancer.